PT  - JOURNAL ARTICLE
AU  - Lyon, Matthew S.
AU  - White, Heather
AU  - Gaunt, Tom R.
AU  - Lawlor, Deborah
AU  - Odd, David
TI  - Automated development of clinical prediction models enables real-time risk stratification with exemplar application to hypoxic-ischaemic encephalopathy
AID  - 10.1101/2022.04.01.22273313
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.01.22273313
4099  - http://medrxiv.org/content/early/2022/04/01/2022.04.01.22273313.short
4100  - http://medrxiv.org/content/early/2022/04/01/2022.04.01.22273313.full
AB  - Real-time updated risk prediction of disease outcomes could lead to improvements in patient care and better resource management. Established monitoring during pregnancy at antenatal and intrapartum periods could be particularly amenable to benefits of this approach. This proof-of-concept study compared automated and manual prediction modelling approaches using data from the Collaborative Perinatal Project with exemplar application to hypoxic-ischaemic encephalopathy (HIE). Using manually selected predictors identified from previously published studies we obtained high HIE discrimination with logistic regression applied to antenatal only (0.71 AUC [95% CI 0.64-0.77]), antenatal and intrapartum (0.70 AUC [95% CI 0.64-0.77]), and antenatal, intrapartum and birthweight (0.73 AUC [95% CI 0.67-0.79]) data. In parallel, we applied a range of automated modelling methods and found penalised logistic regression had best discrimination and was equivalent to the manual approach but required little human input giving 0.75 AUC for antenatal only (95% CI 0.69, 0.81), 0.70 AUC for antenatal and intrapartum (95% CI 0.63, 0.78), and 0.74 AUC using antenatal, intrapartum, and infant birthweight (95% CI 0.65, 0.81). These results demonstrate the feasibility of developing automated prediction models which could be applied to produce disease risk estimates in real-time. This approach may be especially useful in pregnancy care but could be applied to any disease.Competing Interest StatementT.R.G receives funding from Biogen for unrelated research. D.A.L has received support from Medtronic Ltd and Roche Diagnostics for unrelated research.Funding StatementThis study was funded by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, the UK Medical Research Council as part of the MRC Integrative Epidemiology Unit (MC_UU_00011/4 and MC_UU_00011/6). The funders had no role in the study design, collection of data or interpretation of results. The views expressed are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care or Medical Research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CPP data files are freely available for download from the National Archives Catalog (https://www.archives.gov/research/electronic-records/nih.html). Ethical approval was not required for this study as the data were publicly available for unrestricted use as detailed in this note (https://catalog.archives.gov/OpaAPI/media/643929/content/arcmedia/electronic-records/rg-443/CPP/304.1-3ND.pdf).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesStata, R and Python3 code to replicate these analyses are available from https://github.com/MRCIEU/hie-ml. The CPP data files and documentation are available for download from the National Archives Catalog (https://www.archives.gov/research/electronic-records/nih.html) https://github.com/MRCIEU/hie-ml